Page 1684 - Clinical Small Animal Internal Medicine

1622 Index

myxomatous mitral valve disease neosporosis 1005–1006 feline leukemia virus 879
VetBooks.ir cardiogenic shock 414 epidemiology 1005 gait and posture 731–732
fungal infections 992
diagnosis 1006
(MMVD) 245–250
gastritis and gastric ulceration 551
etiology/pathophysiology 1005
cardiovascular disease 119,
122–124 history and clinical signs head trauma 751–752, 752, 758
classification/staging 247 1005–1006, 1006 muscle size/tone and spinal
diagnosis 247–248, 247 signalment 1005 reflexes 732–735
epidemiology 246 treatment and prognosis 1006 myelopathy 815–816, 817,
etiology/pathophysiology neostigmine bromide 806 818–819, 821
245–246 Neotrombicula autumnalis portosystemic shunts and
heart failure 189–190, 193–194 1459–1460 microvascular dysplasia
history and clinical signs nephritic syndrome 1103 714, 718
246–247 nephritis 942, 943 postural reactions 732–733
prognosis 248, 248 nephrogenic diabetes insipidus record keeping 730
treatment 248–250 (NDI) 65–66, 66, 68 sensorium/mental attitude 731
nephroliths 1124, 1149–1156 shock 406
n nephrotoxicity trauma and burns 448
nAChR see nicotinic acetylcholine acute kidney injury 1090 neurologic disease 883–884, 1488
receptors antifungal therapy 1049 neuromuscular disease 570, 770
nasal lymphoma 1237, 1239 antimicrobials 1041, 1044 neuromuscular junction (NMJ)
nasal mycotic rhinitis 1485, 1485 neuroendocrine tumors 1304, diseases 803–809
nasal tumors 1256–1258 1306, 1355 anatomy and physiology 803
diagnosis/staging 1257, 1257 neuroendocrinology 35–41 black widow spider
epidemiology 1257 adenohypophysis and intermediate envenomation 808
etiology/pathophysiology lobe 35–36 drug‐induced neuromuscular
1256–1257 anatomy and physiology 35–40 blockade 808
history and clinical signs 1257 glycoprotein hormones 36–38 myesthenia gravis 803–806
prognosis 1258 hypothalamic‐pituitary hormones postsynaptic disorders 808
signalment 1257 and their primary functions 37 presynaptic disorders 807–808
treatment 1257–1258 hypothalamus 35, 36, 41 snake envenomation 809
nasoesophageal/nasogastric feeding oxytocin 40 neuroophthalmology 823–828
tubes 452, 1097–1098 pituitary gland 35–41, 36 amaurosis 823
nasopharyngeal polyps 791, 1477 proopiomelanocortin‐derived anisocoria 824
NC see neutrophilic cholangitis peptides 38–39 cavernous sinus
N‐cadherin 1210 regulation of hormone secretion 41 syndrome 827–828
NDI see nephrogenic diabetes insipidus regulation of the neuroendocrine dysautonomia 828
necrosis system 40, 40 facial nerve paralysis 826
esophageal disorders 562 somatomammotropic hormones 38 Horner syndrome 827, 827
oral cavity and salivary vascular supply 41 internal and external
glands 544, 545 vasopressin, antidiuretic hormone, ophthalmoplegia 824–825, 825
pancreatitis 593 arginine vasopressin 39 optic neuritis 823, 824
surgical, traumatic, and bite wound neurogenic functional urethral trigeminal nerve deficit
infections 1031 obstruction 1187 825–826, 826
venomous snake bites 463 neurogenic pulmonary edema neurotoxicity
necrotizing leukoencephalitis 388–389 antimicrobials 1046
(NLE) 780–781, 799–801 neurogenic shock 818 botulism 968–970
necrotizing meningoencephalitis neurohypophysis 39–40 neuromuscular junction
(NME) 780–781, 795, neurologic assessment 729–739 diseases 807
799–801 anatomic diagnosis 729–730 neurotrophic/neuroparalytic
negative contrast agents 470, 481 botulism 969 keratitis 825–826, 826
neonatal hypoglycemia 106 components of the neurologic neutraceuticals 1344
neoplasia see malignancies and examination 731–739 neutrophilic cholangitis (NC)
neoplasia cranial nerves 735–739 687–690, 693
Neorickettsia helminthoeca see salmon critical care setting 347, 350 New York Heart Association
poisoning disease differential diagnosis 730 (NYHA) 177–178